Pregnancy outcome following in utero exposure to bisphosphonates

Bone

Volumn 44, Issue 3, 2009, Pages 428-430

  Levy, Shirley ^a   Fayez, Ibrahim ^a   Taguchi, Nobuko ^a   Han, Jung Yeol ^b   Aiello, Jennifer ^a   Matsui, Doreen ^c   Moretti, Myla ^a   Koren, Gideon ^a   Ito, Shinya ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Cheil Hospital   (South Korea)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Birth defects; Bisphosphonates; Drug; Human; Pregnancy

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; FIBROBLAST GROWTH FACTOR 2; PAMIDRONIC ACID; RISEDRONIC ACID; SALAZOSULFAPYRIDINE;

ACROCEPHALOSYNDACTYLY; ARTICLE; BIRTH DEFECT; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GENE MUTATION; GESTATIONAL AGE; HUMAN; OSTEOPOROSIS; PREGNANCY OUTCOME; SPONTANEOUS ABORTION; TERATOGEN TESTING; THERAPEUTIC ABORTION; UNSPECIFIED SIDE EFFECT;

ABNORMALITIES, DRUG-INDUCED; ADULT; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FETUS; GESTATIONAL AGE; HUMANS; OSTEOPOROSIS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES;

EID: 59849124507     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.11.001     Document Type: Article

References (17)

1. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. 339 (1998) 292-299
2. Dunlop D.J., Soukop M., and McEwan H.P. Antenatal administration of aminopropylidene diphosphonate. Ann. Rheum. Dis. 49 (1990) 955
3. Illidge T.M., Hussey M., and Godden C.W. Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin. Oncol. 8 (1996) 257-258
4. Rutgers-Verhage A.R., deVries T.W., and Torringa M.J. No effects of bisphosphonates on the human fetus. Birth Defects Res., A Clin. Mol. Teratol. 67 (2003) 203-204
5. Ornoy A., Wajnberg R., and Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod. Toxicol. 22 (2006) 578-579
6. Sugawara S., Ikegawa S., Izawa Y., et al. Toxicity studies of alendronate on parturition in the rat. Kiso to Rinsyo 121 (1994) 217-223
7. Patlas N., Golomb G., Yaffe P., et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60 (1999) 68-73
8. Graepel P., Bentley P., Fritz H., et al. Reproduction toxicity studies with pamidronate. Arzneimittelforschung 42 (1992) 654-667
9. Watts N.B. Bisphosphonate treatment of osteoporosis. Clin. Geriatr. Med. 19 (2003) 395-414
10. McClung M.R. Bisphosphonates. Endocrinol. Metab. Clin. N. Am. 32 (2003) 253-271
11. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 (1996) 75-85
12. Skidmore D.L., Pai AP Toi A., et al. Prenatal diagnosis of Apert syndrome: report of two cases. Prent Diagn. 23 (2003) 1009-1013
13. Srivastava T., and Alon U.S. Bisphosphonates: from grandparents to grandchildren. Clin. Pediatr. 38 (1999) 687-702
14. Brumsen C., Hamdly N.A., and Papapoulos S.E. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine 76 (1997) 266-283
15. Glorieux F.H., Bishop N.J., Plotkin H., et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 339 (1998) 947-952
16. Liens D., Delmas P.D., and Meunier P.J. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 343 (1994) 953-954
17. Samuel R., Katz K., Papapoulos S.E., et al. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics 94 (1994) 385-389